545 Concord Avenue
Suite 210
Cambridge, MA 02138
United States
857 702 9600
https://www.neurobopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Hyung-Heon Kim | CEO, President, Principal Executive & Director | 625.16k | N/A | 1975 |
Mr. Marshall H. Woodworth | CFO, Principal Financial Officer & Principal Accounting Officer | 154.5k | N/A | 1958 |
Dr. Mi-Kyung Kim | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Robert Homolka | Senior Vice President of Clinical Operations | N/A | N/A | N/A |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
NeuroBo Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.